Yasminn Meireles

Yasminn Meireles

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2025 in Expert Review of Molecular Diagnostics
Verified
Journal Article
Closed access
YMYasminn Meireles
Yasminn Meireles
CHCarlos Pilotto Heming
Carlos Pilotto Heming
VAVeronica Aran
Veronica Aran
This systematic review and meta-analysis of diagnostic test accuracy evaluated the performance of noninvasive liquid biopsy methods for diagnosis of meningioma, the most common primary intracranial neoplasm in adults. Following PRISMA-DTA guidelines, we searched three databases. Data for 2 × 2 contingency tables were extracted, methodological quality was assessed using QUADAS-2, and a bivariate meta-analysis was performed. A total of 23 studies with 27 datasets were included. Pooled sensitivity was 0.78 (95% CI: 0.71 - 0.83) and specificity was 0.82 (95% CI: 0.76 - 0.86), with an area under the curve (AUC) of 0.86. Subgroup analysis showed that seroreactivity assays had the highest accuracy (diagnostic odds ratio or DOR = 67), while emerging technologies like cfDNA methylation showed high potential but were supported by limited data. The evidence was limited by significant publication bias (Deeks' test, p < 0.001), and meta-regression revealed that studies with a lower risk of bias reported significantly lower specificity (p = 0.008). Fluid-based biomarkers show good overall accuracy for meningioma diagnosis, but the current evidence is compromised by methodological bias, suggesting that true performance is more modest than reported. Rigorous, prospective validation of promising approaches like cfDNA methylation and seroreactivity is essential to clarify their clinical utility.

Verified
Journal Article
Open access
PDF file
CHCarlos Pilotto Heming
Carlos Pilotto Heming
YMYasminn Meireles
Yasminn Meireles
VNVivaldo Neto
Vivaldo Neto
VAVeronica Aran
Veronica Aran
Gliomas are malignant central nervous system tumors characterized by poor prognosis and therapy failure. Adenosine triphosphate-binding cassette (ABC) transporters mediate multidrug resistance via chemotherapeutic efflux, yet their roles as biomarkers across glioma subtypes remain unclear. We analyzed adult diffuse glioma mRNA expression (n = 693; n = 325) and DNA methylation (n = 159) datasets from the Chinese Glioma Genome Atlas in silico, stratifying samples according to the 2021 World Health Organization molecular criteria. ABC transporter profiles, patient-matched methylation–expression correlations (n = 26 overlapping patients; 78 paired gene–sample observations), and prognostic values were evaluated using non-parametric tests with false discovery rate (FDR) correction, Kaplan–Meier curves, and multivariable Cox proportional-hazards regression analyses. Transporter expression and methylation varied significantly by histology and grade. ABCC1 expression increased with malignancy, predicting worse overall survival in univariable analysis (p < 0.0001). Meanwhile, strongly correlated ABCB1 and ABCG2 expressions (Spearman’s ρ = 0.80 in grade 4 tumors) were higher in lower-grade gliomas. Progressive hypomethylation occurred with increasing grade, with significant differential methylation in ABCB1 (FDR p < 0.0001) and ABCG2 (FDR p < 0.0001). In patient-matched integrative analyses, only ABCC1 exhibited a significant inverse association between methylation and expression (Spearman’s ρ = −0.58, p = 0.0019). Baseline clinical multivariable Cox regression (n = 139) suggested that higher ABCB1 and ABCG2 methylation (HR = 0.11, p = 0.03; HR = 0.12, p = 0.04 per 1.0-unit β increase, corresponding to HR = 0.80 and 0.81 per 0.1-unit β increase) may act as protective factors independent of age and grade (though attenuated upon IDH adjustment), whereas higher grade and ABCG2 expression (n = 542; HR = 1.03, p = 0.001) emerged as independent risk factors. Specific ABC transporter profiles could serve as candidate prognostic biomarkers in glioma, warranting external and translational validation.